positron emission tomography (PET) scan is an imaging technique that uses radioactive positrons (i.e., positively charged particles with the same mass as an electron) to detect subtle changes in the body's metabolism and chemical activities. A 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) PET scan uses FDG as a radiotracer. A PET scan provides a black-and-white or color-coded image of the function of a particular area of the body, rather than its structure. Functional change precedes structural change in tissues and organs; therefore, PET scans potentially can detect abnormalities earlier than conventional imaging techniques, such as xrays, computed tomography (CT) scans, and magnetic resonance imaging (MRI). PET scans also have greater sensitivity and specificity when compared to conventional imaging because conventional imaging reveals only anatomic detail, not tissue and organ function (Dalrymple-Hay, Rome, Kennedy, Fulham, & McCaughan, 2002; Silvestri, Tanoue, Margolis, Barker, & Detterbeck, 2003) .
PET scan technology and utilization are evolving, but some of the applications of its use include the detection of cancer, response to cancer treatment, evaluation of neurologic diseases (e.g., epilepsy, Alzheimer's disease, dementia), and assessment of heart muscle function. Researchers are using PET technology to further explore the physiology of various disease processes. Additional clinical applications are expected to evolve (Stanfill & Weber, 2002) .
Use in Oncology
The radiotracer most often used during a PET scan is FDG, which has a glucose component. Because malignant tumors utilize glucose and grow at a faster rate than healthy tissue, a PET scan can locate areas of high FDG uptake, which are indicative of tumor growth.
PET scanning has many applications in the diagnosis and treatment of cancer. This imaging method may be used to determine the best location to biopsy, initial tumor staging, response to cancer treatment, postoperative recurrence (especially for patients with rising tumor marker levels and negative conventional imaging findings), and etiology of subtle abnormalities detected by conventional imaging (e.g., to differentiate radiation necrosis from brain tumor recurrence). PET scanning has been used with patients with various cancer diagnoses, such as melanoma, lymphoma, breast, colon, esophageal, head and neck, and small and non- In some situations, PET scanning is limited. For instance, this method is not as accurate as others (e.g., CT, biopsy) in diagnosing and staging noninvasive bronchioloalveolar carcinoma because of the likelihood of a false-negative result (Yap, Schiepers, Fishbein, Phelps, & Czernin, 2002) . Likewise, low-grade sarcomas and hepatocellular, renal cell, and transitional cell carcinomas may cause falsenegative test results. False-positive PET scan results also can occur. Esophagitis caused by reflux or infection may mimic esophageal cancer on PET scanning because the intensity of FDG uptake often is the same. Isolated lung nodules caused by inflammatory processes or infection are difficult to distinguish from small cell lung cancer and may result in a false-positive PET scan. Positron emission tomography (PET) scans use positrons, positively charged particles, to detect metabolic and chemical changes in the body. Although the clinical applications of this technology still are evolving, PET scans are being used to detect cancer and evaluate neurologic disorders, heart muscle function, and response to treatment. In oncology, PET scans may be used to determine biopsy location, stage disease, diagnose cancer recurrence, and discern malignant from benign conditions. PET scans also have led to the incidental diagnosis of cancer. This article reviews patient preparation and PET scan procedures and includes a patient information sheet on PET scanning. Oncology nurses need to be well informed about new technologies used in cancer care, such as PET scans, to better educate and prepare patients to undergo these tests.
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